This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management. The book is written by expert clinicians from Japan, where the universal public health insurance system ensures that FDG PET is widely used in routine oncological practice and cancer screening. It represents an unrivaled and comprehensive resource that will be of value for all healthcare professionals in the field of clinical oncology.

The use of PET (positron emission tomography) has become the standard quality of care for optimal management of patients with cancer. The availability of the hybrid PET/CT (positron emission tomography/computed tomography) scanner has further improved the utility of PET scanning and provides additional benefits to both patients and to the health system. This publication addresses the important issue of appropriateness of the application of PET/CT procedures in different clinical scenarios of many cancers. It is a useful resource for specialists in nuclear medicine and oncology, and aims to make reliable information widely available to those Member States where PET programmes are still in their planning phase or where the use of PET scanning is limited.

At last, here is a comprehensive compilation of the accumulated knowledge on PET and PET/CT in oncology. It covers the entire spectrum from solidly documented indications, such as staging and monitoring of lung and colorectal cancer, to the application of PET/CT in head and neck surgery, gynecology, radiation therapy, urology, pediatrics and others. The chapters are supplemented by an introduction into the underlying techniques of both imaging devices and radiopharmacy.

This pocket book provides clinicians with the necessary information to understand the role of FDG PET/CT in infection and inflammation. It will help both in making appropriate imaging requests with adequate clinical information and in interpreting the report. The coverage encompasses a wide range of topics, including the role of PET/CT in pyrexia of unknown origin, vasculitis, autoimmune diseases, prosthetic joint infections, osteomyelitis and diabetic foot, immunodeficiency disease, and vascular graft surgery. The book will be a very useful guide to a great test that can provide significant assistance in patient management. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, in which leading professionals succinctly explain the importance of nuclear medicine in the diagnosis and management of oncological and non-oncological conditions.

The aim of this book is to provide concise information and quick reference on the basics and practice of PET/CT for beginners. The chapters are written by Nuclear Medicine experts from different countries with enormous experience in PET/CT practice. Starting with the basics of PET/CT describing physics and the use of radiopharmaceuticals in PET/CT, the book explores the principle of PET/CT in radiotherapy planning. The last five chapters explore normal variation, pitfalls and artefacts commonly seen with various routinely used PET radiotracers. The text is enriched by tables and highlighted clinical cases for better understanding. This book will be of interest mostly to nuclear medicine physicians and radiologists, but it may be appealing also to a wider medical community including oncologists and radiotherapists.

This concise, excellently illustrated pocket book provides an up-to-date summary of the science and practice of PET/CT imaging in lung cancer. The coverage encompasses the entire spectrum of lung cancer – pathology, radiological and PET/CT imaging, and management. Readers will also find information on the physics of PET and its use in respiratory gating and radiotherapy planning. The highlights of the book are the exquisite depiction of normal variants, pitfalls, and artifacts and a pictorial atlas of the various types of lung cancer and their manifestations. The contributing authors are well-known and experienced oncologists, pathologists, radiologists, and nuclear physicians. This book has been compiled under the auspices of the British Nuclear Medicine Society. It will be of high value for nuclear physicians, radiologists, referring clinicians and oncologists, and paramedical staff working in these fields

Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology.